Procrit Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Procrit market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to improved product distribution, increasing corporate social responsibility (CSR) initiatives, the rising prevalence of malnutrition, accelerated regulatory approvals, and a growing number of dialysis patients requiring erythropoietin-based treatments.

Growth during the market's forecast period can be attributed to a rise in minimally invasive treatments, the growth of personalized medicines, increasing government investment, a focus on improving patient quality of life, and greater penetration of specialty pharmacies. Key trends during this period include the development of long-acting formulations, advancements in recombinant DNA technology, progress in bioinformatics, the use of CRISPR technology to enhance protein stability, and innovations in glycosylation engineering.

The rising prevalence of anemia is expected to drive the growth of the Procrit market in the coming years. Anemia is a condition where there is a deficiency of healthy red blood cells or hemoglobin, leading to reduced oxygen delivery to tissues. The increasing prevalence of anemia is largely due to factors such as the growing burden of chronic diseases such as kidney failure, cancer, and inflammatory disorders, along with poor nutrition resulting in deficiencies of iron, vitamin B12, and folate. Procrit (epoetin alfa) helps treat anemia associated with chronic kidney disease, chemotherapy, or certain HIV treatments by stimulating red blood cell production, which reduces the need for blood transfusions. According to the National Center for Health Statistics, the prevalence of anemia in people aged 2 and older increased by 9.3% in 2023 compared to 2021, further emphasizing the growth of the Procrit market.

The increasing prevalence of chronic kidney disease is also expected to contribute significantly to the growth of the Procrit market. Chronic kidney disease, which involves the gradual loss of kidney function and the inability to filter waste from the blood, is becoming more common due to factors such as aging populations, obesity, lifestyle choices, and environmental exposures. Procrit (epoetin alfa) is used to treat anemia in patients with chronic kidney disease by stimulating red blood cell production, which helps maintain healthy hemoglobin levels and reduces the need for blood transfusions. As reported by Kidney Research UK in 2023, around 7.2 million people in the UK are living with chronic kidney disease, with 3.25 million in the advanced stages and an additional 3.9 million in the early stages. This number is expected to rise by 2033, supporting the demand for Procrit.

The rising incidence of cancer is another factor expected to boost the Procrit market. Cancer is a group of diseases marked by uncontrolled cell growth that can invade and destroy normal tissues. The increase in cancer cases is due to factors such as an aging population, exposure to risk factors such as smoking, obesity, and environmental pollutants, as well as better diagnostic capabilities that allow for earlier detection. Procrit (epoetin alfa) is used in cancer patients undergoing chemotherapy to treat anemia by increasing red blood cell production, improving energy levels, and reducing the need for blood transfusions. According to the Australian Institute of Health and Welfare, by 2034, Australia is projected to have approximately 209,000 new cancer diagnoses, up from an estimated 169,000 in 2024. Cancer is expected to account for about 30% of deaths in the country that year, contributing to the growing demand for Procrit.

The key company operating in the procrit market is Amgen Inc.

North America was the largest region in the procrit market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in procrit report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the procrit market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Procrit is a brand name for epoetin alfa, a prescription medication used to treat anemia caused by various conditions. It is a synthetic version of erythropoietin, a hormone naturally produced by the kidneys that stimulates the bone marrow to produce red blood cells. Procrit is commonly prescribed for anemia related to chronic kidney disease, chemotherapy-induced anemia in patients with non-myeloid cancers, anemia in patients with HIV or AIDS receiving zidovudine, and anemia in patients undergoing elective surgery to reduce the need for blood transfusions.

The primary indications for Procrit include chronic kidney disease, human immunodeficiency virus (HIV) infection, and chemotherapy. Chronic kidney disease is a condition in which the kidneys gradually lose their ability to filter waste products from the blood. Procrit is distributed through direct sales, pharmaceutical wholesalers, and retail pharmacies, and is used by various end-users, including hospitals, outpatient clinics, and home care settings.

The procrit market research report is one of a series of new reports that provides procrit market statistics, including procrit industry global market size, regional shares, competitors with a procrit market share, detailed procrit market segments, market trends and opportunities, and any further data you may need to thrive in the procrit industry. This procrit market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The procrit market consists of sales of epoetin alfa injections, pre-filled pens, and monitoring products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.